Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
VHIR
Menu
Cortical and lesion remyelination in relapsing-remitting multiple sclerosis patients from the Opicinumab (Anti-LINGO-1) phase II clinical trial (Synergy). A validation study of the T1-weighted and T2-weighted ratio approach (RAPOR)
Share
Tweet
Share
Pin
Close Menu
VHIR
Home
Six Top Stories
Highlights
Research Areas
Facts & Figures
Partners and Acknowledgements
WIDER
Download Summary
VHIR Annual Report 2021